Search Results - "Negricea, Raluca"

S181: THE PHASE III, RANDOMIZED COMMODORE 2 TRIAL: RESULTS FROM A MULTICENTER STUDY OF CROVALIMAB VS ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS NAIVE TO COMPLEMENT INHIBITORS by Röth, Alexander, He, Guangsheng, Brodsky, Andres, Chai‐Adisaksopha, Chatree Chatree, Dumagay, Teresita, Demichelis, Roberta, Höglund, Martin, Kelly, Richard, Lee, Je‐Hwan, Nishimura, Jun‐Ichi, Obara, Naoshi, Risitano, Antonio Maria, Gaya, Anna, Appius, Anita, Gentile, Brittany, Negricea, Raluca, Zhang, Zilu, Buatois, Simon, Han, Bing

Get full text

A Phase I/II Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of Glofitamab As Monotherapy and in Combination with R-ICE Chemoimmunotherapy in Children and Young Adults with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (iMATRIX-GLO) by Burkhardt, Birgit, Rossato, Gianluca, Dixon, Mark, Carlile, David John, Dmytrasz, Steven, Wulff, Jade, Negricea, Raluca, Wulff, Beate

“…Background: Although rare,relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) in children, adolescents, and young adults is an area of high unmet…”
Get full text

Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib/II study of mosunetuzumab (M) with polatuzumab vedotin (Pola) in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (B-NHL) by Budde, L Elizabeth, Ghosh, Nilanjan, Chavez, Julio C., Lossos, Izidore S., Mehta, Amitkumar, Dorritie, Kathleen Anne, Kamdar, Manali K., Negricea, Raluca, Pham, Song, Hristopoulos, Maria, Huw, Ling-Yuh, O'Hear, Carol Elaine, Oki, Yasuhiro, To, Iris, Magid Diefenbach, Catherine S.

“…Abstract only 7520 Background: Mosunetuzumab (M), a full-length, humanized, IgG1 bispecific antibody targeting CD20 and CD3, has shown promising efficacy and…”
Get full text

Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma by Phillips, Tycel J., Olszewski, Adam J, Munoz, Javier, Kim, Tae Min, Yoon, Dok Hyun, Greil, Richard, Westin, Jason, Jaeger, Ulrich, Canales, Miguel, Chen, Cindy, Althaus, Betsy, O'Hear, Carol, Negricea, Raluca, Xie, Yuying, McCord, Ronald, Purev, Enkhtsetseg, Vallurupalli, Anusha

“…Introduction: Despite the curative intent of the R-CHOP regimen in the first-line treatment of diffuse large B-cell lymphoma (DLBCL), 35-40% of patients who…”
Get full text

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study by Budde, L. Elizabeth, Sehn, Laurie H., Matasar, Matthew J., Schuster, Stephen J., Assouline, Sarit, Giri, Pratyush, Kuruvilla, John, Canales, Miguel, Dietrich, Sascha, Fay, Keith, Ku, Matthew, Nastoupil, Loretta, Wei, Michael C., Yin, Shen, Doral, Michelle Y., Li, Chi-Chung, Huang, Huang, Negricea, Raluca, Penuel, Elicia, O'Hear, Carol, Bartlett, Nancy L.

“…Background: FL is associated with frequent relapses and decreasing progression-free intervals with successive lines of conventional therapy. Later-line…”
Get full text

Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial by Assouline, Sarit E, Kim, Won Seog, Sehn, Laurie H., Schuster, Stephen J., Cheah, Chan Yoon, Nastoupil, Loretta J., Shadman, Mazyar, Yoon, Sung-Soo, Matasar, Matthew J, Diefenbach, Catherine, Gregory, Gareth P., Bartlett, Nancy L., Wei, Michael C., Doral, Michelle Y., Yin, Shen, Negricea, Raluca, Li, Chi-Chung, Penuel, Elicia M., Huang, Huang, Budde, L. Elizabeth

“…Sarit Assouline and Won Seog Kim contributed equally. Introduction: Follicular lymphoma (FL) is considered an indolent yet incurable disease characterized by…”
Get full text

ABCL-351: Promising Tolerability and Efficacy Results from Dose-Escalation in an Ongoing Phase Ib/II Study of Mosunetuzumab with Polatuzumab Vedotin (Pola) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL) by Budde, Elizabeth, Ghosh, Nilanjan, Chavez, Julio, Lossos, Izidore S., Mehta, Amitkumar, Dorritie, Kathleen, Kamdar, Manali, Negricea, Raluca, Pham, Song, Hristopoulos, Maria, Huw, Ling-Yuh, OHear, Carol, Oki, Yasuhiro, To, Iris, Diefenbach, Catherine

“…Mosunetuzumab (Mosun), a full-length, humanized, IgG1 CD20xCD3 bispecific antibody, showed promising efficacy/safety for R/R B-NHL (NCT02500407; Assouline, et…”
Get full text

Poster: ABCL-351: Promising Tolerability and Efficacy Results from Dose-Escalation in an Ongoing Phase Ib/II Study of Mosunetuzumab with Polatuzumab Vedotin (Pola) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL) by Budde, Elizabeth, Ghosh, Nilanjan, Chavez, Julio, Lossos, Izidore S., Mehta, Amitkumar, Dorritie, Kathleen, Kamdar, Manali, Negricea, Raluca, Pham, Song, Hristopoulos, Maria, Huw, Ling-Yuh, O’Hear, Carol, Oki, Yasuhiro, To, Iris, Diefenbach, Catherine

Get full text

Oral Abstract: IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study by Budde, Elizabeth L, Sehn, Laurie H, Matasar, Matthew, Schuster, Stephen J, Assouline, Sarit, Giri, Pratyush, Kuruvilla, John, Canales, Miguel, Dietrich, Sascha, Fay, Keith, Ku, Matthew, Nastoupil, Loretta, Wei, Michael C, Yin, Shen, Doral, Michelle Y, Li, Chi-Chung, Huang, Huang, Negricea, Raluca, Penuel, Elicia, O'Hear, Carol, Bartlett, Nancy L

Get full text

Poster: IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study by Budde, Elizabeth L, Sehn, Laurie H, Matasar, Matthew, Schuster, Stephen J, Assouline, Sarit, Giri, Pratyush, Kuruvilla, John, Canales, Miguel, Dietrich, Sascha, Fay, Keith, Ku, Matthew, Nastoupil, Loretta, Wei, Michael C, Yin, Shen, Doral, Michelle Y, Li, Chi-Chung, Huang, Huang, Negricea, Raluca, Penuel, Elicia, O'Hear, Carol, Bartlett, Nancy L

Get full text

IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study by Budde, Elizabeth L, Sehn, Laurie H, Matasar, Matthew, Schuster, Stephen J, Assouline, Sarit, Giri, Pratyush, Kuruvilla, John, Canales, Miguel, Dietrich, Sascha, Fay, Keith, Ku, Matthew, Nastoupil, Loretta, Wei, Michael C, Yin, Shen, Doral, Michelle Y, Li, Chi-Chung, Huang, Huang, Negricea, Raluca, Penuel, Elicia, O'Hear, Carol, Bartlett, Nancy L

Get full text

IBCL-373: Updated Experience from Mosunetuzumab in Multiple Relapsed Follicular Lymphoma: Promising Efficacy from a Phase I Trial by Assouline, Sarit, Kim, Won Seog, Sehn, Laurie H., Schuster, Stephen J., Cheah, Chan Yoon, Nastoupil, Loretta J., Shadman, Mazyar, Yoon, Sung-Soo, Matasar, Matthew J., Diefenbach, Catherine, Gregory, Gareth P., Bartlett, Nancy L., Wei, Michael C., Doral, Michelle Y., Yin, Shen, Negricea, Raluca, Li, Chi-Chung, Penuel, Elicia, Huang, Huang, Budde, L. Elizabeth

“…Follicular lymphoma (FL) often presents with recurrent relapses. Treatment options for patients (pts) with FL who have received ≥2 prior lines of therapy are…”
Get full text

Poster: IBCL-373: Updated Experience from Mosunetuzumab in Multiple Relapsed Follicular Lymphoma: Promising Efficacy from a Phase I Trial by Assouline, Sarit, Kim, Won Seog, Sehn, Laurie H., Schuster, Stephen J., Cheah, Chan Yoon, Nastoupil, Loretta J., Shadman, Mazyar, Yoon, Sung-Soo, Matasar, Matthew J., Diefenbach, Catherine, Gregory, Gareth P., Bartlett, Nancy L., Wei, Michael C., Doral, Michelle Y., Yin, Shen, Negricea, Raluca, Li, Chi-Chung, Penuel, Elicia, Huang, Huang, Budde, L. Elizabeth

Get full text